You Qin1, Fei Peng2, Lisha Ai3, Shidai Mu2, Yuting Li1, Chensu Yang1, Yu Hu4. 1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. 2. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Hubei, 430022, Wuhan, China. 3. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Hubei, 430022, Wuhan, China. ailisha@hust.edu.cn. 4. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Hubei, 430022, Wuhan, China. dr_huyu@126.com.
Abstract
BACKGROUND: Tumor-infiltrating B lymphocytes (TIL-Bs) is a heterogeneous population of lymphocytes. The prognostic value of TIL-Bs in patients with breast cancer remains controversial. Here we conducted this meta-analysis to clarify the association of TIL-Bs with outcomes of patients with breast cancer. METHODS: We searched PubMed, Embase, and Web of Science to identify relevant studies assessing the prognostic significance of TIL-Bs in patients with breast cancer. Fixed- or random-effects models were used to evaluate the pooled hazard ratios (HRs) for overall survival (OS), breast cancer-specific survival (BCSS), disease-free survival (DFS), and relapse-free survival (RFS) in breast cancer. RESULTS: A total of 8 studies including 2628 patients were included in our study. Pooled analyses revealed that high level of TIL-Bs was associated with longer OS (pooled HR = 0.42, 95% CI 0.24-0.60), BCSS (pooled HR = 0.66, 95% CI 0.47-0.85), and DFS/RFS (pooled HR = 0.41, 95% CI 0.27-0.55). CONCLUSIONS: This meta-analysis suggests that TIL-Bs could be a promising prognostic marker for breast cancer. Novel therapeutic strategies for breast cancer treatment could be developed by enhancement of B cell-mediated antitumor immunity.
BACKGROUND:Tumor-infiltrating B lymphocytes (TIL-Bs) is a heterogeneous population of lymphocytes. The prognostic value of TIL-Bs in patients with breast cancer remains controversial. Here we conducted this meta-analysis to clarify the association of TIL-Bs with outcomes of patients with breast cancer. METHODS: We searched PubMed, Embase, and Web of Science to identify relevant studies assessing the prognostic significance of TIL-Bs in patients with breast cancer. Fixed- or random-effects models were used to evaluate the pooled hazard ratios (HRs) for overall survival (OS), breast cancer-specific survival (BCSS), disease-free survival (DFS), and relapse-free survival (RFS) in breast cancer. RESULTS: A total of 8 studies including 2628 patients were included in our study. Pooled analyses revealed that high level of TIL-Bs was associated with longer OS (pooled HR = 0.42, 95% CI 0.24-0.60), BCSS (pooled HR = 0.66, 95% CI 0.47-0.85), and DFS/RFS (pooled HR = 0.41, 95% CI 0.27-0.55). CONCLUSIONS: This meta-analysis suggests that TIL-Bs could be a promising prognostic marker for breast cancer. Novel therapeutic strategies for breast cancer treatment could be developed by enhancement of B cell-mediated antitumor immunity.
Entities:
Keywords:
Breast cancer; Meta-analysis; Prognosis; Tumor-infiltrating B lymphocytes
Authors: S Loi; S Michiels; R Salgado; N Sirtaine; V Jose; D Fumagalli; P-L Kellokumpu-Lehtinen; P Bono; V Kataja; C Desmedt; M J Piccart; S Loibl; C Denkert; M J Smyth; H Joensuu; C Sotiriou Journal: Ann Oncol Date: 2014-03-07 Impact factor: 32.976
Authors: Florent Petitprez; Aurélien de Reyniès; Emily Z Keung; Tom Wei-Wu Chen; Cheng-Ming Sun; Julien Calderaro; Yung-Ming Jeng; Li-Ping Hsiao; Laetitia Lacroix; Antoine Bougoüin; Marco Moreira; Guillaume Lacroix; Ivo Natario; Julien Adam; Carlo Lucchesi; Yec Han Laizet; Maud Toulmonde; Melissa A Burgess; Vanessa Bolejack; Denise Reinke; Khalid M Wani; Wei-Lien Wang; Alexander J Lazar; Christina L Roland; Jennifer A Wargo; Antoine Italiano; Catherine Sautès-Fridman; Hussein A Tawbi; Wolf H Fridman Journal: Nature Date: 2020-01-15 Impact factor: 49.962
Authors: Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Beth A Helmink; Sangeetha M Reddy; Jianjun Gao; Shaojun Zhang; Rafet Basar; Rohit Thakur; Keren Yizhak; Moshe Sade-Feldman; Jorge Blando; Guangchun Han; Vancheswaran Gopalakrishnan; Yuanxin Xi; Hao Zhao; Rodabe N Amaria; Hussein A Tawbi; Alex P Cogdill; Wenbin Liu; Valerie S LeBleu; Fernanda G Kugeratski; Sapna Patel; Michael A Davies; Patrick Hwu; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Reetakshi Arora; Scott Woodman; Emily Z Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N Spencer; Elizabeth M Burton; Lauren E Haydu; Alexander J Lazar; Roberta Zapassodi; Courtney W Hudgens; Deborah A Ledesma; SuFey Ong; Michael Bailey; Sarah Warren; Disha Rao; Oscar Krijgsman; Elisa A Rozeman; Daniel Peeper; Christian U Blank; Ton N Schumacher; Lisa H Butterfield; Monika A Zelazowska; Kevin M McBride; Raghu Kalluri; James Allison; Florent Petitprez; Wolf Herman Fridman; Catherine Sautès-Fridman; Nir Hacohen; Katayoun Rezvani; Padmanee Sharma; Michael T Tetzlaff; Linghua Wang; Jennifer A Wargo Journal: Nature Date: 2020-01-15 Impact factor: 69.504
Authors: Liubov A Tashireva; Nataliya O Popova; Anna Yu Kalinchuk; Viktor E Goldberg; Elena I Kovalenko; Elena V Artamonova; Aleksey G Manikhas; Dmitriy M Ponomarenko; Nataliya V Levchenko; Elena I Rossokha; Svetlana Yu Krasilnikova; Marina A Zafirova; Evgeniy L Choynzonov; Vladimir M Perelmuter Journal: Front Oncol Date: 2022-06-23 Impact factor: 5.738